OCCIDENT
Venture capitalMunich · Pre-Seed–Series A · 4 people tracked
Find your way into OCCIDENT
1,265 people in our graph share verified history with the OCCIDENT team — schools, employers, funds. One of them is your warm intro.
Investment thesis
OCCIDENT invests in deep-tech startups that transfer promising scientific findings into concrete applications, financing spin-offs from research whose innovations address societal challenges and create value. The firm invests its own capital, takes a long-term view focused on sustainable success potential, and supports portfolio companies financially and with entrepreneurial experience. Its focus areas include life sciences and biotechnology as well as industrial tech. Positioning itself as 'The Science Investor,' OCCIDENT emphasizes an entrepreneurial mindset in portfolio management, from deal sourcing and due diligence through closing and active support, aiming to bring innovations to market success 'the OCCIDENT way.'
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from the firm's website
What they invest in
from 15 of 20 portfolio companiesMedical Devices ×9Biotech ×8Deep Tech ×6Healthtech ×4Advanced Manufacturing ×2Digital Health ×2Hardware ×2Media & Entertainment ×2
HQs:Switzerland×6Germany×4Slovenia×1
Investments · 20 tracked
founders shown can be your intro pathBy year:2024 · 12022 · 12 dated
Algiax Pharmaceuticals is a clinical-stage biotech company developing small-molecule GABAA receptor modulators to treat neuropathic pain and other conditions with high unmet medical need.
BiotechMedical DevicesErkrath, DE
Dr. Guido Koopmans(Chief Scientific Officer)Dr. Birgit Hasse(Head of CMS and Regulator Affairs)
Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments.
BiotechDeep TechMedical DevicesZürich, CH
Jan Nelis(CEO)in
Co-investorsKickfundanother.vcBackbone VenturesVenture Kick
Altavo develops non-invasive silent speech technology using RF sensing and artificial intelligence to help patients who have lost their voice regain natural-sounding speech.
AI & Machine LearningDeep TechMedical DevicesDresden, DE
Rudolf
Co-investorsNovalis Biotech
Avelo develops diagnostic technology aimed at closing the diagnostic gap in respiratory disease, so patients receive timely and accurate information for effective treatment.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsPrivilège Ventures
Chipmetrics provides 3D metrology solutions using test chips and wafers for semiconductor process control, serving semiconductor manufacturers and material developers optimizing deposition processes and yields.
Advanced ManufacturingDeep TechHardwareSemiconductors
Co-investorsInnovestor VenturesRedstoneInnovestor
Core Sensing develops integrated wireless sensor systems that measure force, torque, and other physical quantities directly on components, delivering data to cloud platforms and dashboards for condition monitoring and predictive maintenance applications.
Advanced ManufacturingHardwareIoT
EBAMed develops non-invasive cardiac ablation technology using particle/proton beam therapy to treat cardiac arrhythmias, with in-house R&D focused on medical devices and cardiac software.
HealthtechMedical Devices
Giovanni Leo(Co-Founder)Douglas Packer(Co-Founder & Key Advisor)Ugo Amaldi(Co-Founder & Key Advisor)Marina Izzo(Chief Executive Officer & Director)inAdriano Garonna(Chief Technology Officer)inOlivier Coquoz(Head of R&D)
Co-investorsElysia CapitalLIFTT
Startup that credited Venture Kick with helping establish its customer and market focus.
Co-investorsSICTICVenture Kick
Lunaphore develops spatial biology solutions that enable scientists and clinicians to analyze tissue structure and cellular composition.
BiotechDeep TechMedical DevicesLausanne, CH
Co-investorsPolytech Ecosystem VenturesZühlke Ventures
Co-investorsCDP Venture Capital
Resistell develops a nanomotion-based diagnostic device for rapid phenotypic antibiotic susceptibility testing (AST), aimed at accelerating detection of antibiotic resistance in hospital settings.
BiotechHealthtechMedical Devices
Dr. Danuta Cichocka(CEO, Co-Founder, Board Member)inGrzegorz Gonciarz(COO)inDr. Alex Sturm(Chief Scientific Officer)inMartin Birk(CFO)in
Co-investorsAlpana VenturesTRUMPF Venture
StartupTicker is a Swiss platform that maintains a public database of over 200 venture capitalists, business angel clubs, and corporate venture funds that have invested in Swiss startups.
Media & EntertainmentSector AgnosticSwitzerland, CH
Co-investorsSICTIC
Thermosome is a drug development company working on targeted tumor therapy combined with immune stimulation, using a tumor targeting approach designed to increase local drug concentrations for better treatment outcomes in cancer patients.
BiotechHealthtech
Co-investorsBayern Kapital
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersBioMedPartnersFrazier Life SciencesFund+Nextech Invest
GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with a focus on acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma, urea cycle disorders, and organic acidemias.
BiotechDigital HealthMedical Devices
Co-investorsVerve Ventures
Exits · 2
IPOs and acquisitions across the tracked portfolioTubulis GmbHacq. by Gilead SciencesVersantisacq. by GENFIT
Portfolio news
latest coverage across their companiesImmitra Bio · ggba.swiss · Aug 3, 2026
InSphero · natlawreview.com · May 21, 2026
Altavo · finsmes.com · Jan 23, 2026
Chip Metrics · chipmetrics.com · Dec 3, 2025
Frequently asked questions
- How many investments has OCCIDENT made?
- OCCIDENT has 20 tracked investments, 2 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
- What stage does OCCIDENT invest at?
- OCCIDENT invests at the Pre-Seed, Seed, Series A stages.
- What sectors does OCCIDENT focus on?
- OCCIDENT focuses on Advanced Manufacturing, Biotech, Deep Tech, Hardware, Healthtech.
- Where is OCCIDENT located?
- OCCIDENT is headquartered in Munich, DE.
- Who does OCCIDENT co-invest with?
- OCCIDENT most often shares deals with SICTIC, CDP Venture Capital, Frazier Life Sciences, among 21 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Fly Ventures is an early-stage venture firm that backs founders at the zero-to-one stage, with portfolio companies going on to raise substantial follow-on funding from top US and European VCs.
Hyderabad Angels is an angel investment network founded in 2010, comprising entrepreneurs, industrialists, and family offices that back early-stage startups across India with capital and mentorship.
Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.
AlleyCorp is an early-stage investor and incubator based in New York that builds and backs companies across enterprise, consumer, healthcare, and deep tech sectors.